Applications of Crotamiton in Industrial Manufacturing

As an established chemical raw material producer, we support downstream manufacturers by supplying high-purity Crotamiton for specialized industrial sectors. Our material meets stringent regulatory and quality requirements suitable for global use. Below, we outline key application scenarios based on verified industry demand, manufacturing processes, and standards compliance.

1. Topical Pharmaceutical Preparations (Antipruritic Creams and Lotions)

Pharmaceutical companies utilize Crotamiton as an active ingredient in prescription and over-the-counter antipruritic dermatological formulations, particularly for relief in scabies and chronic itching disorders. Production entails strict adherence to pharmacopoeial monographs and GMP protocols, with dosage precision critical for patient safety and product registration. The compound integrates during the active blending phase, where process controls govern homogeneity and drug release profiles. Finished products include medicated creams, lotions, and topical emulsions sold in regulated healthcare channels.

Industry compliance standards

• United States Pharmacopeia (USP)
• European Pharmacopoeia (EP)
• Good Manufacturing Practice (GMP, ICH Q7A)
• 21 CFR part 210/211 (FDA drug manufacturing regulations)

Typical usage ratio

• 5–10% w/w in topical formulas, adjusted based on therapeutic indication and dermal absorption studies

Downstream process integration

• Direct addition during the emulsion phase following base preparation and prior to shear homogenization

Final product types

• Antipruritic creams (scabies treatment)
• Anti-itch lotions for atopic or contact dermatitis
• Prescription medicated ointments
• Pediatric antipruritic preparations

2. Veterinary Dermal Treatments

Animal health manufacturers incorporate Crotamiton as a key antiparasitic and antipruritic agent for dermatological veterinary products. The application ensures animal welfare compliance and efficacy against mite infestations in companion and farm animals. Production strictly observes veterinary medicine guidelines, with drug loading tailored to species and indication. The ingredient enters at the active incorporation stage, typically via low-shear mixing to preserve stability and uniform distribution. End products target companion animals and livestock, supporting veterinarians and animal care providers worldwide.

Industry compliance standards

• VICH GL guidelines (Veterinary International Conference on Harmonization)
• European Medicines Agency (EMA) veterinary requirements
• US FDA Center for Veterinary Medicine (CVM) guidance

Typical usage ratio

• 5–15% w/w, with variation based on animal species, formulation type, and regulated maximum residue limits

Downstream process integration

• Addition during the semi-solid base formation, with in-process QC to verify drug dispersion and stability

Final product types

• Antiparasitic creams for dogs and cats
• Topical lotions for livestock mite management
• Veterinary itch relief rubs

3. Medical Device Lubricants and Coatings

Medical device manufacturers use Crotamiton as a functional excipient in specific lubricating gels and coatings applied to non-invasive medical devices and accessories, optimizing patient comfort and reducing friction. Its well-characterized biocompatibility profile enables integration into regulated Class I and II devices, provided performance and risk assessments confirm safe use. The compound disperses uniformly during the gel or coating preparation stage, contributing to the tactile and handling properties of the finished device. Output includes gels for electrode contact, lubricated catheters, and selected probe covers.

Industry compliance standards

• ISO 10993 (Biocompatibility for medical devices)
• ISO 13485 (Medical devices – QMS requirements)
• FDA 21 CFR 820 (Quality System Regulation)

Typical usage ratio

• 2–8% w/w, depending on device type and functional performance requirements

Downstream process integration

• Mixed into aqueous or hydroalcoholic gel matrix before final viscosity adjustment and device application

Final product types

• Electrode conductive gels
• Lubricating gels for catheters and tubing
• Coating solutions for diagnostic probe sheaths

4. Personal Care Anti-Itch Products

Personal care and cosmeceutical producers employ Crotamiton as an active or quasi-active component in non-prescription anti-itch consumer products, focusing on rapid relief for minor skin irritations. Formulators adhere to cosmetic and quasi-drug regulations specific to regional markets, ensuring safety and clear labeling for over-the-counter distribution. Addition occurs at the active incorporation or cooling phase, maintaining ingredient stability throughout mixing and packaging. Finished goods include anti-itch gels, sprays, and soothing creams that are marketed through pharmacies and retail channels.

Industry compliance standards

• EU Cosmetics Regulation (EC) No 1223/2009
• Japan Quasi-Drug Standard (MHLW)
• US FDA OTC Monograph System (as applicable)

Typical usage ratio

• Up to 10% w/w, subject to national cosmetic or quasi-drug limitations and stability data

Downstream process integration

• Dispersed in the formulation during the low-temperature mixing phase to minimize degradation

Final product types

• Over-the-counter anti-itch gels
• After-bite soothing creams
• Skin-cooling sprays for minor irritation relief